CA2256720A1 - Formulation et methode pour traiter l'insuffisance cardiaque congestive - Google Patents

Formulation et methode pour traiter l'insuffisance cardiaque congestive Download PDF

Info

Publication number
CA2256720A1
CA2256720A1 CA002256720A CA2256720A CA2256720A1 CA 2256720 A1 CA2256720 A1 CA 2256720A1 CA 002256720 A CA002256720 A CA 002256720A CA 2256720 A CA2256720 A CA 2256720A CA 2256720 A1 CA2256720 A1 CA 2256720A1
Authority
CA
Canada
Prior art keywords
formulation
moxonidine
dosage form
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002256720A
Other languages
English (en)
Inventor
John Leeper Mcnay Jr.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2256720A1 publication Critical patent/CA2256720A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne une méthode pour traiter l'insuffisance cardiaque congestive, consistant à administrer une quantité efficace de 4-chloro-5-(imidazoline-2-y(amino)-6-méthoxy-2-méthylpyrimidine) dans une formulation, orale ou sous forme d'implant, à libération non immédiate et des formulations à libération non immédiate.
CA002256720A 1996-06-06 1997-06-05 Formulation et methode pour traiter l'insuffisance cardiaque congestive Abandoned CA2256720A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65946396A 1996-06-06 1996-06-06
US08/659,463 1996-06-06

Publications (1)

Publication Number Publication Date
CA2256720A1 true CA2256720A1 (fr) 1997-12-11

Family

ID=24645503

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002256720A Abandoned CA2256720A1 (fr) 1996-06-06 1997-06-05 Formulation et methode pour traiter l'insuffisance cardiaque congestive

Country Status (17)

Country Link
EP (1) EP0914128A1 (fr)
JP (1) JP2000511906A (fr)
KR (1) KR20000016406A (fr)
CN (1) CN1226166A (fr)
AU (1) AU3233197A (fr)
BR (1) BR9709546A (fr)
CA (1) CA2256720A1 (fr)
CZ (1) CZ397698A3 (fr)
EA (1) EA199900006A1 (fr)
HU (1) HUP0003885A2 (fr)
IL (1) IL126966A0 (fr)
NO (1) NO985695L (fr)
PL (1) PL330637A1 (fr)
TR (1) TR199802496T2 (fr)
WO (1) WO1997046241A1 (fr)
YU (1) YU55998A (fr)
ZA (1) ZA974978B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19815411A1 (de) * 1998-04-06 1999-10-07 Solvay Pharm Gmbh Thermogenese stimulierend wirksame Arzneimittel
AU2727400A (en) * 1999-01-29 2000-08-18 Eli Lilly And Company Moxonidine salts
CN1166363C (zh) 1999-02-01 2004-09-15 索尔瓦药物有限公司 莫索尼定在制备治疗心肌梗塞造成的心肌损伤的药物中的应用
DE602006018139D1 (de) * 2006-08-31 2010-12-23 Chemagis Ltd Verwendung der Monoxidinssalze zur Reinigung von Monoxidin
KR100812287B1 (ko) * 2007-01-03 2008-03-13 주식회사 챠콜코리아 내면에 반사층을 갖는 신호등 갓

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4323570A (en) * 1978-11-15 1982-04-06 Beiersdorf Aktiengesellschaft Substituted aminopyrimidines
DE3617158C2 (de) * 1986-05-22 1994-10-06 Lohmann Therapie Syst Lts Transdermales Arzneimittel
DE3729299A1 (de) * 1987-09-02 1989-03-23 Beiersdorf Ag Transdermales therapeutisches system
DE3904795C2 (de) * 1989-02-17 2000-10-12 Lilly Pharma Produktion Gmbh & Pharmazeutisches Präparat und dessen Verwendung
DE4325491A1 (de) * 1993-07-29 1995-02-02 Boehringer Ingelheim Kg Verwendung von zentral wirksamen alpha-2-Agonisten zur Hemmung des Postaggressionsstoffwechsels
DE4423177A1 (de) * 1994-07-01 1996-01-04 Kali Chemie Pharma Gmbh Antihyperglykämisch wirksame Arzneimittel
CA2182851A1 (fr) * 1995-08-15 1997-02-16 August Masaru Watanabe Methode de traitement d'un etat resultant de l'arret de la consommation abusive de drogues

Also Published As

Publication number Publication date
HUP0003885A2 (hu) 2001-04-28
YU55998A (en) 1999-11-22
PL330637A1 (en) 1999-05-24
IL126966A0 (en) 1999-09-22
TR199802496T2 (xx) 1999-02-22
ZA974978B (en) 1998-12-07
NO985695D0 (no) 1998-12-04
CZ397698A3 (cs) 1999-05-12
BR9709546A (pt) 1999-08-10
AU3233197A (en) 1998-01-05
KR20000016406A (ko) 2000-03-25
NO985695L (no) 1999-02-04
EP0914128A1 (fr) 1999-05-12
EA199900006A1 (ru) 1999-06-24
JP2000511906A (ja) 2000-09-12
WO1997046241A1 (fr) 1997-12-11
CN1226166A (zh) 1999-08-18

Similar Documents

Publication Publication Date Title
RU2346703C2 (ru) Синергетические комбинации, которые содержат ингибитор ренина, предназначенные для лечения сердечно-сосудистых заболеваний
AU2003303631B2 (en) Multilayer Dosage Forms Containing NSAIDs and Triptans
JP2937376B2 (ja) 徐放性医薬組成物
JP4758064B2 (ja) 有効物質を徐放する３−（３−ジメチルアミノ−１−エチル−２−メチル−プロピル）フェノール含有医薬
RU2298418C2 (ru) Комбинация по меньшей мере двух соединений, выбранных из групп антагонистов at1-рецептора или ингибиторов асе (ангиотензинпревращающий фермент), или ингибиторов hmg-coa-редуктазы (бета-гидрокси-бета-метилглутарил-кофермент-а-редуктаза)
US7741374B1 (en) Methods of use of fenofibric acid
EA002720B1 (ru) Терапевтическая композиция для введения толтеродина с контролируемым высвобождением и способ лечения мочевого пузыря с её использованием
BRPI0610634A2 (pt) combinação para a terapia de hiperplasia benigna da próstata
JP2009173669A (ja) 持続放出コーティングまたはマトリックスおよびｎｍｄａ受容体アンタゴニストを含む組成物、そのようなｎｍｄａアンタゴニストの被験体への投与方法
PL186745B1 (pl) Preparat farmaceutyczny zawierający inhibitor ACE, ramipryl i związek dihydropirydynowy
CZ16809U1 (cs) Farmaceutická tableta zahrnující matrici tablety a tamsulosin
JP5982020B2 (ja) 嘔吐および下痢などの状態を解消または軽減するためのコーティングされた薬物球状体およびその用途
US20030194440A1 (en) Pharmaceutical composition for sustained release of the hmg-coa reductase inhibitor fluvastatin
RU2724338C2 (ru) Фармацевтическая комплексная композиция, включающая амлодипин, лозартан и розувастатин
NL8701335A (nl) Orale farmaceutische preparaten.
CN109414423A (zh) 包含丙戊酸的延迟释放药物制剂和其用途
CA2256720A1 (fr) Formulation et methode pour traiter l'insuffisance cardiaque congestive
KR20040032977A (ko) 신규 지연 방출 경구 투여 제형
WO2005042022A2 (fr) Combinaison nouvelle
MXPA98010056A (en) Formulation and method for dealing with insufficienciacardiac, congest
TW201725038A (zh) 藉由曲線下面積（ａｕｃ）給與奧美沙坦（ｏｌｍｅｓａｒｔａｎ）之劑量的方法
JP2003523981A (ja) モルシドミンの放出時間延長を伴う経口投与用新規生薬製剤
KR20190001340A (ko) 이바브라딘을 포함하는 서방성 약제학적 조성물 및 이의 제조방법
JP2016504390A (ja) ロラゼパムの徐放性製剤
WO2024109927A1 (fr) Composition pharmaceutique comprenant du potassium d'azilsartan médoxomil et un bloqueur de canal calcique, son procédé de préparation et son utilisation

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued